Sign up
Pharma Capital

Alliance Pharma’s morning sickness drug gets marketing authorisation in the UK

The AIM-listed pharmaceutical company also said that the MHRA has approved the brand name Xonvea, which will be used for marketing Dicelctin in the UK
pregnant woman
Alliance Pharma estimates peak sales for Xonvea in the UK of approximately £10mln

Alliance Pharma plc (LON:APH) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the UK Marketing Authorisation Application for Diclectin, a prescription product for the treatment of nausea and vomiting of pregnancy.  

The AIM-listed pharmaceutical company also said that the MHRA has approved the brand name Xonvea, which will be used for marketing Dicelctin in the UK.

READ: Alliance Pharma gets boost as morning sickness drug gets UK regulatory green light

The company said it anticipates Xonvea’s launch in autumn this year as the only medicine licensed in the UK for the treatment of nausea and vomiting during pregnancy.

Alliance Pharma estimates peak sales for Xonvea in the UK of approximately £10mln and £30mln across the other nine European countries at peak sales. 

Peter Butterfield, Alliance Pharma's chief executive officer, said: "There are currently no licensed treatments for nausea and vomiting of pregnancy in the UK so this is excellent news for patients and clinicians as it fulfils a significant unmet medical need."

View full APH profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.